Recent news coverage includes general market and geopolitical developments but does not directly pertain to Quantum Genesis AI Corp.'s business or operations.

• Stocks rallied on a push for diplomacy to end the US-Iran war, reflecting broader market optimism [N1].
• The US dollar remained little changed while awaiting news on US-Iran peace talks [N2].
• The dollar faced pressure from sliding bond yields and rising stocks [N3].
• Cotton posted early gains in trading [N4].
• European markets closed weak after a cautious session [N5].
• Recent 13F filings showed changes in holdings of major investors [N6].
• Cocoa prices retreated as higher prices sparked hedge selling by producers [N7].
• Arabica coffee prices slipped on optimism about the Brazil coffee crop [N8].

Quantum Genesis AI Corp. leverages advanced scientific principles such as quantum mechanics and molecular modeling to engineer enzymes that offer environmental and efficiency benefits in pharmaceutical manufacturing. Its proprietary technology and pending patent application for ibuprofen enzyme synthesis provide a foundation for licensing revenue streams. The company's focus on clean and green chemistry aligns with growing sustainability trends and ESG considerations. By targeting a widely produced drug like ibuprofen, the company addresses a large potential market. The planned partnerships with third-party manufacturers and distributors could enable scalable commercialization without heavy capital investment in manufacturing infrastructure.

Quantum Genesis AI Corp. is an early-stage company with no revenues and significant net losses, raising substantial doubt about its ability to continue as a going concern without additional financing. The enzyme engineering field is highly competitive, with established players possessing greater resources and earlier market presence. Technical challenges in enzyme specificity, stability, scale-up, and regulatory compliance may delay or impede commercialization. The company's reliance on third-party manufacturers for production and regulatory approvals introduces execution risks. The pending patent application has not yet been granted, and intellectual property rights were only recently formalized. Financial constraints and limited operational history increase the risk of failure to achieve commercial success.

Quantum Genesis AI Corp.'s moat lies in its proprietary enzyme design technologies and computational methodologies, including a pending patent application for enzymatic synthesis of ibuprofen. The company's approach integrates quantum mechanics and molecular modeling to engineer enzymes with enhanced activity and specificity, targeting environmental and efficiency improvements in pharmaceutical manufacturing. However, the company is in an early development stage with limited operational history and faces competition from well-established biotechnology firms with greater resources and earlier market presence. The company's strategy to license its technology rather than manufacture enzymes directly may limit operational risks but also depends on successful partnerships and market adoption. The formalization of intellectual property rights strengthens its competitive position, but the lack of revenues and financial constraints pose challenges to sustaining and expanding its moat.

• Going Concern and Liquidity Risk: The company has incurred significant net losses and has a working capital deficit, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Dependence on External Financing: Quantum Genesis AI Corp. is dependent on raising capital through equity or debt offerings or strategic partnerships to fund operations and development plans.
• Competition: The company faces competition from well-established biotechnology firms with greater financial, research, and operational resources, which may limit its market penetration.
• Technical and Regulatory Challenges: Engineering enzymes with high specificity, stability, and scalability is complex. Regulatory approvals for enzyme use in pharmaceutical manufacturing may be costly and time-consuming, with compliance falling on third-party manufacturers.
• Intellectual Property Risks: The patent application is pending and was only recently formally assigned to the company. There is risk related to patent protection, enforcement, and potential third-party claims.
• Operational Dependence on Third Parties: The company relies on third-party manufacturers and distributors for enzyme production and commercialization, which may introduce risks related to capacity, quality, and regulatory compliance.

• Quantum Genesis AI Corp. (formerly Quantumzyme Corp.) is a biotransformation company focused on clean and green chemistry, specifically developing engineered enzymes for active pharmaceutical ingredient (API) production, initially targeting ibuprofen manufacturing.
• The company applies quantum mechanics, molecular modeling, and enzyme engineering to enhance enzyme activity, selectivity, and specificity.
• Their first engineered product is an enzyme for pharmaceutical API production of ibuprofen, targeted at generic drug manufacturers.
• Quantum Genesis AI Corp. is in the process of identifying third-party manufacturers and distributors to scale and distribute their enzyme product.
• The company holds proprietary enzyme design technologies and computational methodologies acquired via an Asset Purchase Agreement dated February 21, 2023.
• They have a pending U.S. patent application (US20250146029A1) for modified polypeptides for enzymatic synthesis of ibuprofen, filed November 2, 2023, with formal assignment of rights to the company effective as of that date.
• The company intends to license its engineered enzyme to major API manufacturers and pharmaceutical companies, generating revenue through technology transfer and royalties.
• Third-party manufacturers will be responsible for regulatory approvals and compliance, including FDA and other agencies, as Quantum Genesis AI Corp. itself will not initially be subject to regulatory oversight for the enzyme product.
• The company is currently in the development stage and has not generated revenue as of January 31, 2026.
• Financial snapshot as of January 31, 2026: cash and equivalents of $59, current assets $59, current liabilities $418,401, resulting in a working capital deficit of $418,342.
• The company reported no revenue and a net loss of approximately $4.33 million for the three months ended January 31, 2026, and a net loss of approximately $4.38 million for the six months ended January 31, 2026.
• Diluted earnings per share was -$0.12 as of January 31, 2026.
• Operating expenses decreased compared to prior periods due to lower professional fees but are expected to increase with business activity.
• The company has substantial doubt about its ability to continue as a going concern due to net losses, accumulated deficits, and working capital deficit, and is dependent on raising additional capital.
• The enzyme engineering industry is dynamic and evolving, with applications across pharmaceuticals, fragrances, flavors, sustainable materials, plastic degradation, and carbon capture.
• Challenges in enzyme engineering include achieving substrate specificity, enzyme stability, cofactor requirements, immobilization, scale-up, cost-effective production, regulatory compliance, and protein folding complexities.
• The company faces competition from well-established enzyme manufacturers and biotechnology firms with greater resources and earlier market presence.
• Quantum Genesis AI Corp. has one employee, the CEO, who also serves as CFO, with plans to establish a Scientific Advisory Board.
• The company’s business model focuses on licensing enzyme technology rather than direct manufacturing or regulatory approval responsibilities.
• The company’s intellectual property rights were formalized through an Assignment Agreement dated April 9, 2026, confirming transfer of patent application rights from the CEO to the company.
• The company’s principal executive office is located in San Diego, California.
• The company’s financial figures and liquidity ratios are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.